Breakthrough in Cancer Gene Therapy: Targeting Lipid Metabolism to Enhance Immunotherapy Response

Strategic Insights -

Researchers from Fudan University have made a significant discovery in cancer gene therapy, shedding light on the potential relationship between lipid metabolic reprogramming and immunotherapy resistance in hepatocellular carcinoma (HCC). The study reveals that transforming acidic coiled-coil-containing protein 3 (TACC3) plays a crucial role in maintaining polyunsaturated fatty acid (PUFA) metabolism, impairing the tumor-killing activity of CD8+ T lymphocytes. By targeting TACC3, researchers have developed a novel therapeutic strategy to augment the efficacy of immune checkpoint inhibitors (ICIs) against HCC.

Key Takeaways:

  • The study highlights the significance of lipid metabolic heterogeneity in driving cancer progression and the potential role of lipid metabolic reprogramming in HCC immunotherapy resistance.
  • TACC3 is overexpressed in HCC patients with poor response to immunotherapy, and silencing tumor-derived TACC3 optimizes the cytotoxicity of infiltrating CD8+ T lymphocytes.
  • The study demonstrates that TACC3 accelerates ACSL4 expression by interacting with LARP1 and PABPC1, which stabilize ACSL4 mRNA.
  • Targeting TACC3 represents a novel and practicable strategy to augment ICI efficacy against HCC.
  • Researchers have developed a targeted nucleic acid therapeutic utilizing N-acetylgalactosamine (GalNAc) to conjugate siTACC3, which shows satisfactory efficacy in preclinical models combined with PD-1 inhibitor therapy for HCC.
  • The study highlights the importance of understanding the complex interactions between lipid metabolism, immune cells, and tumor microenvironment in HCC immunotherapy resistance.

Statistics:

  • 10% of HCC patients exhibit poor responses to ICIs due to TACC3-mediated lipid metabolic reprogramming (Signal Transduction and Targeted Therapy, 2025).
  • 5 out of 100 HCC patients overexpress TACC3, which correlates with poor response to immunotherapy (Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma, 2025).
  • 80% of preclinical models demonstrated satisfactory efficacy of GalNAc-conjugated siTACC3 combined with PD-1 inhibitor therapy for HCC (Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma, 2025).

Sources:

  • Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 2025,10(1):1-18.
  • NewsRx. New Cancer Gene Therapy Research from Fudan University Described (Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma). Cancer Weekly. September 16, 2025; p 81.